Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Applied for Selection of “Prime Market” segment of the Tokyo Stock Exchange

12/06/2021 | 02:12am EST

TOKYO, December 6 , 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today applied for selection of the "Prime Market" segment of the Tokyo Stock Exchange, Inc. ("TSE") as its listing market as determined at the Board of Directors Meeting held on November 19, 2021.

Astellas received the results of the initial assessment made by the TSE on July 9, 2021, confirming Astellas' compliance with the listing requirements for the "Prime Market" in the new market segments that will be introduced on April 4, 2022 by the TSE.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 06 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 December 2021 07:11:04 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
01/24ASTELLAS PHARMA : Meeting Script(3,989KB)
PU
01/20ASTELLAS PHARMA : Digital Transformation of Astellas Pharma(3,351KB)
PU
01/20ASTELLAS PHARMA : We posted the presentation material for media briefing on Digital Transf..
PU
01/19Essa Pharma Commences Dosing in Phase 1/2 Clinical Trial of Prostate Cancer Combo Thera..
MT
01/16Glenmark Pharmaceuticals Unit Gets US FDA's Approval for Regadenoson Injection
MT
01/10Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
AQ
01/10Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System M..
MT
01/07Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
MT
01/07Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
DJ
01/07Modalis Announces Termination of Research Collaboration on MDL-204
CI
More news
Financials
Sales 2022 1 334 B 11 700 M 11 700 M
Net income 2022 184 B 1 613 M 1 613 M
Net cash 2022 380 B 3 333 M 3 333 M
P/E ratio 2022 19,7x
Yield 2022 2,58%
Capitalization 3 594 B 31 545 M 31 524 M
EV / Sales 2022 2,41x
EV / Sales 2023 2,13x
Nbr of Employees 15 455
Free-Float -
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 939,50 JPY
Average target price 2 505,83 JPY
Spread / Average Target 29,2%
EPS Revisions
Managers and Directors
Kenji Yasukawa Executive Officer
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.3.69%31 545
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093